UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                        Date of report (Date of earliest
                                event reported):
                                September 2, 2009

                           HEMISPHERX BIOPHARMA, INC.
               (Exact Name of Registrant as Specified in Charter)

                           Delaware 0-27072 52-0845822
             (State or Other Jurisdiction (Commission (IRS Employer
               of Incorporation) File Number) Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania, 19103
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

================================================================================






8.01 Other Events

We announced today that insufficient votes were obtained for passage of proposal
no. 3 contained in the proxy for the 2009 Annual Meeting of  Stockholders.  With
this  proposal  being the sole purpose of the  adjourned  Stockholders'  Meeting
scheduled for September, 4, 2009, this meeting has been cancelled.

For more  information,  please see the September 2, 2009 press release  attached
hereto as exhibit 99.1.


The following Exhibit is filed as part of this report:

Exhibit No.                Description

99.1                      Press Release dated September 2, 2009
 -------------------------------------------------------------------------------









                                            Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date: September 2, 2009

                                      HEMISPHERX BIOPHARMA, INC.

                                     /s/ William A. Carter
                                     -----------------------------------
                                      William A. Carter, M.D.,
                                      Chief Executive Officer


Company/Investor Contact:                                    Exhibit 99.1
Exhibit 99.1
Dianne Will
Hemispherx Biopharma, Inc.
518-398-6222
ir@hemispherx.net
- -----------------

 Hemispherx Biopharma Announces Cancellation of Adjourned Stockholders' Meeting

PHILADELPHIA,  PA--September  2,  2009--Hemispherx  Biopharma  (NYSE AMEX:  HEB)
announced  today that  insufficient  votes were obtained for passage of proposal
no. 3 contained in the proxy for the 2009 Annual Meeting of  Stockholders.  With
this  proposal  being the sole purpose of the  adjourned  Stockholders'  Meeting
scheduled  for  September,  4,  2009,  there is no need to hold the  meeting  on
September 4th.

As previously  announced,  the 2009 Annual Meeting of  Stockholders  was held as
scheduled  on June 24, 2009 at which  three of the four  proposals  passed.  The
Company left the polls open with regard to voting on proposal 3, an amendment of
its Certificate of Incorporation to increase the number of authorized  shares of
Common Stock from  200,000,000 to 350,000,000,  and adjourned the meeting solely
with regard to this proposal.  The Company did this due to the low vote turn out
and the requirement  that this proposal be approved by the holders of a majority
of the outstanding shares. Less than the requisite number of shares for approval
of the proposal were present at the original meeting.

The Company  believes that the low turnout of Stockholders as of the May 8, 2009
Record  Date was due to the fact that more  than 40% of its  outstanding  shares
were held  outside  the  United  States  with many of these  shares  are held at
European banks that do not  necessarily  participate in the voting of proxies of
American companies.

About Hemispherx Biopharma
Hemispherx  Biopharma,  Inc.  is a  specialty  pharma  company  engaged  in  the
manufacture  and clinical  development  of new drug  entities  for  treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(R)  (FDA approved for a category of sexually  transmitted  diseases)
and the  experimental  therapeutics,  Ampligen(R)  and Oragens.  Ampligen(R) and
Oragens  represent  experimental  RNA nucleic acids being developed for globally
important debilitating diseases and disorders of the immune system. Hemispherx's
platform  technology  includes  large and small agent  components  for potential
treatment  of  various  severely  debilitating  and life  threatening  diseases.
Hemispherx has in excess of 50 issued patents  comprising its core  intellectual
property estate and a fully commercialized product (Alferon N Injection(R)). The
Company  wholly  owns and  exclusively  operates a GMP  certified  manufacturing
facility in the United  States for  commercial  products.  For more  information
please visit www.hemispherx.net.

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications; similarly, the completion of
the NDA filing  process  with  Ampligen(R)  does not imply that the product will
ever be approved commercially.